No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide.
The effect of an oral treatment with thioridazine (100 or 200 mg daily) on plasma concentrations of carbamazepine (CBZ) and its active metabolite carbamazepine-10,11-epoxide (CBZ-E) was studied in eight epileptic patients stabilized on CBZ therapy. No significant changes in steady-state plasma levels of CBZ and CBZ-E occurred, suggesting that CBZ metabolism is not apparently affected by thioridazine.
Spina
E
E
Institute of Pharmacology, University of Messina, Italy.
Amendola D'Agostino
A M
AM
Ioculano
M P
MP
Oteri
G
G
Fazio
A
A
Pisani
F
F
D000328:Adult; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy; D005260:Female; D006706:Homeostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D013881:Thioridazine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
D002220:Carbamazepine; D013881:Thioridazine; C012227:carbamazepine epoxide